Substance / Medication

Rotigotine

Overview

Active Ingredient
rotigotine
RxNorm CUI
616739
Labeler: UCB, Inc.Updated: 2025-06-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

NEUPRO is contraindicated in patients who have demonstrated hypersensitivity to rotigotine or the components of the transdermal system.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

10 trials linked to this intervention

10
Total Trials
0
Recruiting
9
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
Sun Weibo, Wang Qingyong, Yang Tiansong et al. · Neurol Sci · 2022
PMID: 35691972Meta-Analysis
Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.
Chen Fei, Jin Lingjing, Nie Zhiyu · J Pharm Pharm Sci · 2017
PMID: 28810946Meta-Analysis
Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
Antonini A, Chaudhuri K R, Boroojerdi B et al. · Eur J Neurol · 2016
PMID: 27425586Meta-AnalysisFull text (PMC)
Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of randomized placebo-controlled trials.
Ding Jun, Fan Wei, Chen Hong-Hui et al. · J Huazhong Univ Sci Technolog Med Sci · 2015
PMID: 25877347Meta-Analysis
Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
Zhou Chang-Qing, Li Shan-Shan, Chen Zhong-Mei et al. · PLoS One · 2013
PMID: 23936090Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rotigotine (substance)
SNOMED CT
421924006
UMLS CUI
C1700683
RxNorm CUI
616739
Labeler
UCB, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
10
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.